Dennis J. Slamon, MD

Dennis J. Slamon, MD

Breast Medical Oncology
Primary Location
Santa Monica Parkside Cancer Care
2336 Santa Monica Boulevard
Suite 304
Santa Monica, California 90404


Dennis J. Slamon, MD, PhD serves as director of Clinical/Translational Research, and as director of the Revlon/UCLA Women's Cancer Research Program at JCCC. He is a professor of medicine, chief of the Division of Hematology/Oncology and executive vice chair for research for UCLA's Department of Medicine. Slamon also serves as director of the medical advisory board for the National Colorectal Cancer Research Alliance, a fund-raising organization that promotes advances in colorectal cancer.

For 12 years, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of the new breast cancer drug Herceptin, which targets a specific genetic alteration found in about 25 percent of breast cancer patients. To acknowledge Slamon's accomplishments, President Clinton appointed Slamon to the three-member President's Cancer Panel in June 2000.

A 1975 honors graduate of the University of Chicago's Pritzker School of Medicine, Slamon earned his PhD in cell biology that same year. He completed his internship and residency at the University of Chicago Hospitals and Clinics, becoming chief resident in 1978. One year later, he became a fellow in the Division of Hematology/Oncology at UCLA.

Patient Stories

Breast Cancer Drug Herceptin a Life Saver


Medical Board Certification

Internal Medicine, American Board of Internal Medicine, 1978


UCLA School of Medicine, 1982


University of Chicago Hospitals, 1979


University of Chicago Hospitals, 1976


University of Chicago Pritzker School of Medicine, MD, 1975

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center


  • Dr. Slamon has won nearly a dozen national research awards honoring his scientific endeavors.
    • Top Doctors, Los Angeles Magazine, 2021
    • Warren Alpert Foundation Scientific Prize and 2007 Gairdner Foundation International Award for his work in the development of Herceptin.
    • Dr. Slamon received the Fifth Aultman Cancer Center Award from Kent State University and the David A. Karnofsky Memorial Award and Lecture at the American Society of Clinical Oncology honoring his work in the development of Herceptin, a molecularly targeted breast cancer therapy.
    • In 2004, the American Cancer Society presented Slamon with the Medal of Honor, the top award bestowed by the organization.
    • In 2003, Slamon received the Dorothy P. Landon-AACR Prize for Translational Cancer Research, an international award given by the Kirk A. and Dorothy P. Landon Foundation and the American Association for Cancer Research.
    • In 2001, Slamon was awarded the Wadsworth Center's Brown-Hazen Award for Excellence in the Basic Sciences, and in 2002, he received the Jeffrey A. Gottlieb Memorial Award from the M.D. Anderson Cancer Center in Texas.
    • In 2000, Slamon was awarded the Translational Medicine Award by the USCD-Salk Institute as well as the Bristol-Myers Squibb Oncology Millennium Award for significant achievement and leadership in breast cancer research.